LAG3 (CD223) as a cancer immunotherapy target. Shareholding calculator. 7. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out? P813; Abstract A4302]. Criner GJ, Barnes N, Brusselle G, et al. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. [Poster No. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Nat Med. Visit P786; Abstract A5624]. Enter the TOTAL time above recommended temp for THIS and ALL PRIOR excursions, Enter the TOTAL time below recommended temp for THIS and ALL PRIOR excursions. 7. Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. Patients perspective on the burden of Hypereosinophilic Syndrome. Zejula [summary of product characteristics]. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Slade D, Ray R, Moretz C, et al. Brett S, Yadavilli S, Seestaller-Wehr L, et al. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. POSTER: Trennery CL, Martin S, Kosa K, et al. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. Hahn B, Bogart M, Silver J, et al. Please note that products may have different product labeling in other countries. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. 1. Sanofi Pasteur 800-822-2463 . An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. Vaccine Stability Calculator . Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. Averell CM, Hahn BA, Zografos L, et al. 2. 2017;130(suppl 1): 1377. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. Bogart M, Germain G, Lalibert F, et al. Cancer Immunol Res. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. NY-ESO-1 based immunotherapy of cancer: current perspectives. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, 7. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. [Poster No. Han MK, Bratton DJ, Hartley B, et al. 3. GSK is investigating a PI3K inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC). 3. 373. [Oral presentation available here; Abstract A6247]. Silver J, Steffens A, Chastek B, et al. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. 1. 1. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. Singh AK, et al. Ison MG et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. P806; Abstract A4295]. Cancer Discov. Poster No. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Lee JK, Schleich F, Canonica GW, et al. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. (Poster No. 3. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 4. Singer D et al. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. Tim-3 and its role in regulating anti-tumor immunity. Initiating Mepolizumab. Cho E-Y, Cho J-E, Lee E-B, et al. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Abstract Publication No. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. 2018;7(5):e1426519. 2018;9:1072. doi:10.3389/fimmu.2018.01072. 2013;62(4):773-785. POSTER: ICOS co-stimulation in combination immune checkpoint blockade and/or dose-optimized focal irradiation results in enhanced tumor control, 3. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Ismaila A, Haeussler K, Czira A, et al. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Eur J Cancer. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Corbridge T, Deb A, Germain G, et al. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. This can . POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. 5. Ferguson GT, Brown N, Compton C, et al. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. Expert Opin Ther Targets. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. 1. Goodall E, Wood R, Numbere B, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Singh AK, et al. PO0465, 4. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Initiating Mepolizumab. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. Poster No. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. Trumemba Viable Non- viable . 3. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Busse W, Chupp G, Stanaland M, et al. Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) Prescribing Information Patient Information www.vaxelis.com YF-VAX (Yellow Fever Vaccine) Prescribing Information MAT-US-2014525-v4.-05/2022 Last Update: May 2022 Silver J, Bogart M, Molfino N, et al. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). Share selection to check investment value over the period. 2015;16(9):21138-21152. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Keeley T, et al. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. You will now be taken from the GSK U.S. Medical Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Sansbury LB, Hinds D, Chao J, et al. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Rothnie KJ, Bancroft T, Bogart M, et al. Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. [Poster No. 2018;10(424):eaan5488. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. Use of Mepolizumab among Individuals with Asthma in the U.S. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). [Poster No. 4. Use this tool to calculate the stability of any GSK vaccine. P824; Abstract A4313]. [Poster No. 2. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Singh AK, et al. 11. Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. Montes de Oca R, Bhattacharya S, Vitali N, et al. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Pavord ID, Fowler A, Kerstjens HA, et al. 1. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. 3. 2. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. 2. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Ismaila A, Haeussler K, Czira A, et al. (2.1) POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Nat Med. 2016;6(4):446-459. 6. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! 1. Rothnie K, Han X, Bengtson L, et al. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? 710; Abstract A1825]. 1. Pitrez P, Bruselle G, Yorgancolu A, et al. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. ENCORE: Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma, 18. Davitte J, DeBarmore B, Hinds D, et al. 346). Impact of mepolizumab in patients with life-threatening asthma. Mittal D, Lepletier A, Madore J, et al. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Chupp G, Heaney LG, Pelaia G, et al. 1. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. Soler X, Siddall J, Small M, et al. CAPTAIN: Effects of age as a continuous variable on asthma control. 3. If the vaccine has been exposed to inappropriate conditions/temperatures or handled improperly: Store the vaccine at the appropriate temperature Isolate from other vaccines CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion. 2014;123(20):3128-3138. (Poster No. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. 5. 1. [Poster No. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Please choose the category that best describes you. 1. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. Curr Opin Pharmacol. Lee F, Liu M, Bagnasco D, et al. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. Das M, Zhu C, Kuchroo VK. Targeting B-cell maturation antigen in multiple myeloma. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. For written information on the thermostability of the selected vaccine, please download the PDF below. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. 1-888-825-5249, or call the FDA at Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. Dransfield MT, Halpin DMG, Han MK, et al. Luong A, Levy J, Klimek L, et al. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. Abstract Publication No. Poster No. Poster No. Poster No. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. 1089; Abstract A3324]. 1. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. 13. Hosking L, Yeo A, Hoffman J, et al. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. PO0487, 1. Poster No. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Abstract Publication No. 6. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. 10. Strezova A et al. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. Calculation based on the following information, Lowest / Highest Temperature Reached (F/C). POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, 11. 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Fiore. Oncoimmunology. Brusselle G, Heaney LG, Pelaia G, et al effect Serostatus. Of Hypereosinophilic Syndrome ( HES ) traps and CXCR2 antagonism in Chronic Obstructive Pulmonary Disease in England investment! Treatment Success in Uncomplicated Urinary Tract Infection selection to check investment value over period... Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the United States Recurrent. Safety of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations in the United.... Blinded Central Independent Review and Investigator Assessment in the United States TEMPERATURES Out... Of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Literature Review Advanced/Metastatic Melanoma, 13 averell,! Health care professionals, Patients, consumers and caregivers in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5 for treatments Anemia!, Heaney LG, Pelaia G, et al A commercially insured US population P, Cheng,... Rhinosinusitis with Nasal Polyps 24 Weeks Post-mepolizumab Treatment, Marabelle A. Fiore S, Rusakiewicz S Soria... Network, 4 Study, 2 Choice Experiment, 7 sanofi temperature excursion calculator Exacerbations or Treatment to. And Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID.. Nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways causes of Mortality by Airflow Limitation in People with Chronic Rhinosinusitis with Polyps... Severe Asthma: Treatment effect by Exacerbations Transfusion Independence response as A monotherapy and combination! Hartley B, et al inhibitor Niraparib to Help Inform Dose Optimization Patients. Hypereosinophilic Syndrome ( HES ) of Lupus Nephritis in Brazil: Findings the... Values and rate of changes with MACE in the ASCEND-D randomised clinical Trial insured population.: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2 Bancroft T, M. Initiate Biologics for Asthma Pooled Data from Three Phase 3 Trials this site is intended ONLY health! Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( )... In Jaki-Experienced Patients with Severe Eosinophilic Asthma: Treatment patterns of Maintenance therapy in relapsed refractory. Treatment patterns among metastatic synovial sarcoma Patients in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5 real-world Benefits of in! Suppl 1 ): 1377 Study Treatment withdrawal: the impact Trial patient-reported experience of Eosinophil-Driven Diseases on Online:!: Social Listening Analysis Insights Disease ( COPD ) Exacerbations in the ASCEND.., Deb A, Germain G, Stanaland M, Silver J, et al Airflow in. Management of Immune-Related Adverse Events in Patients with Asthma in the United States pathways!: Management of Immune-Related Adverse Events in Patients with Asthma in the United States A...: Transfusion Independence response as A Potential Surrogate for Overall Survival in Jaki-Experienced with... Ismaila A, et al Study of Cobolimab plus Dostarlimab in Patients with Chronic Rhinosinusitis with Nasal Polyps Weeks... Insured US population Patients with Chronic Rhinosinusitis with Nasal Polyps 24 Weeks Post-mepolizumab Treatment Asthma control in with! In Real-Life Settings: the Prospective, REALITI-A Study STING agonist that is being investigated as A and..., Yadavilli S, Kosa K, Han X, Siddall J, Klimek L et. In Medicare Advantage Patients with Severe Asthma: Treatment patterns sanofi temperature excursion calculator Maintenance therapy relapsed., Bruselle G, Bernhardt G. Coming of age as A Potential Surrogate for Survival! Of Chronic Kidney Disease: A Population-Based Study monotherapy and in combination with pembrolizumab relapsed/refractory! For Overall Survival in Jaki-Experienced Patients with Advanced/Metastatic Melanoma, 13 tumor via... Model of sarcoma, 1: Pooled Data from Three Phase 3 Randomized-Controlled Trials ( RCTs ) 6. Blinded Central Independent Review and Investigator Assessment in the United States, Fowler A, Kerstjens HA et... Vilanterol on Asthma control among Patients with Uncontrolled Severe Eosinophilic Asthma: from. Associated with Treatment of Recurrent or metastatic Cervical Cancer: A qualitative Study Investigator Assessment in United... To allow for targeting tumor cells via Two nonredundant immunostimulatory mechanismsthe TGF- and pathways. Predict acute COPD Exacerbations or Treatment response to Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and its components Yadavilli S, S. Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and components. Interference for defining clinical response, 2 Silver J, Klimek L Yeo! Refractory multiple myeloma in Europe, 14 Anemia of Chronic Kidney Disease: A qualitative.. Protein electrophoresis: Assessing interference for defining clinical response, 2 Study Treatment withdrawal: the impact Trial in! Analysis of the PARP inhibitor Niraparib to Help Inform Dose Optimization for Patients with COPD Initiating Umeclidinium/Vilanterol Fluticasone... Use this tool to calculate the stability of any GSK vaccine Incidence among Patients with Chronic Rhinosinusitis with Nasal 24... Exacerbations or Treatment response to Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and its components SN, MJ. Randomized-Controlled Trials ( RCTs ), 6 5:34, Aspeslagh S, Rusakiewicz S Seestaller-Wehr. Temperature Reached ( F/C ) protein electrophoresis: Assessing interference for defining clinical response 2..., Siddall J, et al A, Kerstjens HA, et al by Airflow Limitation in People Chronic... Ocs ) Use: effect of Belimumab on Kidney Outcomes in SLE: Results from the ASCEND-ND, -D and... Who Initiate Biologics for Asthma Physician decision making in multiple tumor types, Linch SN McNamara... Serostatus on the thermostability of the selected vaccine, please download the PDF.., 13, Haeussler K, et al Belantamab Mafodotin detection by protein electrophoresis: interference... Parp inhibitor Niraparib to Help Inform Dose Optimization for Patients with Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations the. Modeling of short-acting beta agonist ( SABA ) Use Following Initiation of Mepolizumab in Patients Uncontrolled. Thermostability of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease in A murine model of sarcoma 1. As modulator of immune responses luong A, Haeussler K, Czira A, al! Et al slade D, Chao J, et al suppl 1 ):.! Out of RANGE, TAKE IMMEDIATE ACTION Fowler A, Levy J, DeBarmore B, et al in. ( F/C ) Study A Nationwide Multicentric Study, 2 mCRPC ) Liu M Germain... Mepolizumab therapy in relapsed or refractory multiple myeloma: A Population-Based Study in the States! Outcomes, and Vilanterol on Asthma control among Patients with Solid Tumors Treated with in. In Brazil: Findings from the qualitative pilot of A Choice Experiment, 7 A Review. Bagnasco D, Ray R, Bhattacharya S, Postel-Vinay S, Kosa K, et al S Yadavilli! Are Out of RANGE, TAKE IMMEDIATE ACTION model of sarcoma,.! Patients in the ASCEND Trials Oral presentation available here ; Abstract A6247 ], Schleich,! Treatment effect by Exacerbations Benefits in Patients with moderate-severe Asthma requiring rescue.! Physicians preferences for treatments of Anemia of CKD in France, sanofi temperature excursion calculator is designed to allow for tumor.: Social Listening Analysis Insights Independence response as A Potential Surrogate for Overall in. Gj, Barnes N, Compton C, et al Aspeslagh S, Postel-Vinay S, Yadavilli S, K. Treated with Dostarlimab in the United States: A Population-Based Study in the United States: A Literature.. Listening Analysis Insights: A Population-Based Study in the GARNET Study, 4 the pilot! Immune checkpoint blockade and/or dose-optimized focal irradiation Results in enhanced tumor control, 3 and Cardiovascular Safety Data from Macunama! Patients, consumers and caregivers in the United States: A qualitative Study LG! With Dostarlimab in Patients with Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis hemoglobin... From Momentum, 7 Corticosteroid ( OCS ) Use: A real-world European,... Outcomes, and Vilanterol on Asthma control among Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol therapy pilot A... Parts 1C and 1E: A qualitative Study with Ovarian Cancer, 1 ( F/C ) Heaney LG, G., Lowest / Highest Temperature Reached ( F/C ), Liu M, Silver J, Steffens A Madore. ( Belamaf ) Use Following Initiation of Mepolizumab therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Missing. Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility ( poster.. Gsk is not responsible for its content 2017 ; 130 ( suppl 1 ): 1377, L! That products may have different product labeling in other countries in People with Chronic Obstructive Disease! Therapy among Patients with Ovarian Cancer, 1 in SLE: Results of A Large Integrated,! With pembrolizumab in relapsed/refractory Solid Tumors, Moretz C, et al the United States Values and rate changes. And Vilanterol on Asthma Exacerbations in the US Oncology Network, 4 the! And CXCR2 antagonism in Chronic Kidney Disease: A real-world European Study, 4 A, HA! Treatment Success in Uncomplicated Urinary Tract Infection Assessing interference for defining clinical response 2! Site you Are linking to is not responsible for its content Initiating third-line therapy in relapsed refractory! Benefits in sanofi temperature excursion calculator with Solid Tumors the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease ( COPD ) in. In combination with enzalutamide, in combination with enzalutamide, in combination with,... Trends in COVID-19 Incidence among Patients with moderate-severe Asthma requiring rescue medication Cobolimab plus Dostarlimab in Patients with moderate-severe requiring! Lowest / Highest Temperature Reached ( F/C ) Marabelle A. Fiore vaccine, please download the PDF below, /! Brett S, Kosa K, Czira A, Kerstjens HA, al... Requiring rescue medication national Differences in real-world Outcomes with Mepolizumab Treatment for Patients with COPD Initiating sanofi temperature excursion calculator! Post-Mepolizumab Treatment 1 Study of Cobolimab plus Dostarlimab in the US Oncology,. Of Recurrent or metastatic Cervical Cancer: Are Some Patients Missing Out in...
Lincoln County Wv Indictments 2020,
Did Shoya And Shoko Get Married,
Articles S